|Bid||115.00 x 1100|
|Ask||159.00 x 800|
|Day's range||120.12 - 123.68|
|52-week range||120.12 - 203.16|
|Beta (5Y monthly)||1.14|
|PE ratio (TTM)||22.95|
|Earnings date||31 Oct 2022 - 04 Nov 2022|
|Forward dividend & yield||0.28 (0.23%)|
|Ex-dividend date||20 Oct 2022|
|1y target est||172.42|
PerkinElmer's (PKI) T-Cell Select reagent kit is expected to allow for a more automated workflow following the FDA's approval.
WALTHAM, Mass., September 22, 2022--PerkinElmer’s (NYSE: PKI) Oxford Immunotec today announced the U.S. Food and Drug Administration (FDA) has approved the use of the T-Cell Select™ reagent kit for the automation of its T-SPOT®.TB test workflow for in vitro diagnostic (IVD) use by certified laboratories.
PerkinElmer (PKI) continues to gain from solid product portfolio despite forex woes.